<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<page>
<body bgcolor="#FFFFFF">
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td height="4" valign="bottom" bgcolor="#000000"></td>
  </tr>
  <tr>
    <td height="2" valign="top"></td>
  </tr>
  <tr>
    <td height="1" valign="top" bgcolor="#000000"></td>
  </tr>
</table>
<p align="center">&nbsp;</p>
<p align="center"><font size="2" face="serif">SECURITIES AND EXCHANGE COMMISSION<br>
  WASHINGTON, D.C. 20549</font></p>
<hr align="center" width="20%" size="1" noshade>
<p align="center"><font size="2" face="serif">FORM 8-K</font></p>
<p align="center"><font size="2" face="serif">CURRENT REPORT<br>PURSUANT TO SECTION 13 OR 15(d) OF<br>THE SECURITIES EXCHANGE ACT OF 1934</font></p>
<p align="center"><font size="2" face="serif">Date of Report (Date of earliest event reported):  November 14, 2005</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">Savient Pharmaceuticals, Inc.</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr align="center" width="100%" size="1" noshade></td>
</tr>
<tr valign="top">
  <td align="center"><font size="2" face="serif">(Exact name of registrant as
    specified in charter)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" >
  <td align="left">&nbsp;</td>
  <td align="right">&nbsp;</td>
  <td align="right">&nbsp;</td>
</tr>
<tr valign="top" >
<td align="left"><div align="center"><font size="2" face="serif">Delaware</font></div></td>
<td width="33%" align="right"><div align="center"><font size="2" face="serif">0-15313                </font></div></td>
<td width="33%" align="right"><div align="center"><font size="2" face="serif">13-3033811</font></div></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><div align="center"><font size="2" face="serif">(State or other juris-<br>
  diction of incorporation</font></div></td>
<td align="center"><div align="center"><font size="2" face="serif">(Commission<br>
  File Number)</font></div></td>
<td align="center"><div align="center"><font size="2" face="serif">(IRS Employer<br>
  Identification No.)</font></div></td>
</tr>
</table>
<br><br>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">One Tower Center, 14th Floor</font><br><font size="2" face="serif">East Brunswick, New Jersey 08816</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr align="center" width="100%" size="1" noshade></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Address of principal executive offices) (Zip Code)</font></td>
</tr>
</table>
<p align="center"><font size="2" face="serif">Registrant&#8217;s telephone number, including area code:  (732) 418-9300</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif">Not applicable</font></td>
</tr>
<tr valign="top">
  <td align="center"><hr align="center" width="100%" size="1" noshade></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Former name or former address, if changed since last report)</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td width="3%"><div align="center"><font size="2" face="serif"><img src="emptybox.gif" width="12" height="12"></font></div></td>
<td align="left"><font size="2" face="serif">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><div align="center"><font size="2" face="serif"><img src="emptybox.gif" width="12" height="12">&nbsp;</font></div></td>
<td align="left"><font size="2" face="serif">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td><div align="center"></div></td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><div align="center"><font size="2" face="serif"><img src="emptybox.gif" width="12" height="12"></font></div></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))</font></td>
</tr>
</table>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
  <td><div align="center"></div></td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td width="3%"><div align="center"><font size="2" face="serif"><img src="emptybox.gif" width="12" height="12"></font></div></td>
<td align="left"><font size="2" face="serif">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td>
</tr>
<tr valign="top">
  <td>&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
</table>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td height="1" valign="top" bgcolor="#000000"></td>
  </tr>
  <tr>
    <td height="2" valign="top" bgcolor="#FFFFFF"></td>
  </tr>
  <tr>
    <td height="4" valign="bottom" bgcolor="#000000"></td>
  </tr>
</table>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="left"><font size="2" face="serif"><b>Item 3.01.  Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On November 14, 2005, Savient Pharmaceuticals, Inc. (the &#8220;Company&#8221;) received a Nasdaq staff determination letter stating that the Company is not in compliance with Nasdaq Marketplace Rule 4310(c)(14) because the Company has not timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2005.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The full text of the press release issued in connection with the receipt of the Nasdaq staff determination letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 9.01.&nbsp;&nbsp;Financial Statements
      And Exhibits</b></font></p>
<p align="left"><font size="2" face="serif">(d) Exhibits</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" >
<td width="6%" align="right"><div align="left"><font size="2" face="serif">99.1</font></div></td>
<td width="89%" align="left"><font size="2" face="serif">Press release dated November 18, 2005</font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>
<p align="center"><font size="2" face="serif">SIGNATURE</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>  <table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="left"><font size="2" face="serif">Date:  November 18, 2005</font></td>
<td colspan="2" align="left"><font size="2" face="serif">SAVIENT PHARMACEUTICALS, INC.</font></td>
</tr>
<tr valign="top">
  <td colspan="2" align="right">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td colspan="2" align="right"><font size="2" face="serif">By:&nbsp;&nbsp;</font></td>
<td align="left"><font size="2" face="serif"><u>/s/ Philip K. Yachmetz&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></font></td>
</tr>
<tr valign="top">
<td colspan="2" align="left"><font size="2" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">Philip K. Yachmetz</font><br><font size="2" face="serif">Senior Vice President &#150; Corporate</font><br><font size="2" face="serif">   Strategy, General Counsel and Secretary</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b409902_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 9003}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "051216099"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):  November 14, 2005
Savient Pharmaceuticals, Inc.
(Exact name of registrant as
    specified in charter)
Delaware
0-15313
13-3033811
(State or other juris-
diction of incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:  (732) 418-9300
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2{b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 3.01.  Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 14, 2005, Savient Pharmaceuticals, Inc. (the "Company") received a Nasdaq staff determination letter stating that the Company is not in compliance with Nasdaq Marketplace Rule 4310(c)(14) because the Company has not timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2005.
The full text of the press release issued in connection with the receipt of the Nasdaq staff determination letter is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01.  Financial Statements
      And Exhibits
(d) Exhibits
99.1
Press release dated November 18, 2005
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:  November 18, 2005
SAVIENT PHARMACEUTICALS, INC.
By:
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Senior Vice President – Corporate
Strategy, General Counsel and Secretary